Gastroesophageal cancer patients with HER2-positive tumors now have compelling evidence for a potentially superior treatment approach that could extend survival where traditional therapies have failed. This represents a critical advance for one of the most challenging cancer types, where five-year survival rates remain stubbornly low despite decades of research effort. The investigation centered on zanidatamab, a novel bispecific antibody that simultaneously targets two distinct sites on the HER2 protein, creating a more comprehensive blockade than conventional single-target therapies. When tested as a standalone treatment and in combination with the checkpoint inhibitor tislelizumab, zanidatamab demonstrated meaningful clinical activity in patients whose cancers had progressed despite prior HER2-directed treatments. The bispecific design represents a meaningful evolution in precision oncology, moving beyond the limitations of single-pathway inhibition that has defined HER2-targeted therapy since trastuzumab's introduction. Unlike traditional monoclonal antibodies that bind one HER2 epitope, zanidatamab's dual-targeting mechanism may overcome common resistance patterns that allow tumors to escape therapy. This dual-blocking strategy aligns with emerging evidence that cancer cell survival often depends on redundant signaling pathways rather than single molecular drivers. The gastroesophageal cancer setting presents particular challenges, as these tumors typically exhibit greater heterogeneity and treatment resistance compared to breast cancers where HER2 targeting first proved successful. While these results suggest zanidatamab could fill an important therapeutic gap, the gastroesophageal cancer field has seen promising early results fail to translate into practice-changing outcomes. The true measure will be whether this bispecific approach can deliver the sustained, clinically meaningful survival benefits that have remained elusive in this aggressive disease.